OOIR: Observatory of International Research

Papers

(The TQCC of Experimental Hematology & Oncology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome	136
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	135
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	120
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	110
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	103
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	97
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	79
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	71
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	61
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	59
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	59
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	58
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	54
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	53
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	52
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	51
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	51
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	50
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	48
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	48
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	47
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	47
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas	43
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	42
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	42

Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	41
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	40
Breast cancer heterogeneity and its implication in personalized precision therapy	39
Role of m6A writers, erasers and readers in cancer	38
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	37
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	37
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	37
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	35
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	35
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	34
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	34
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways	33
TCR engineered T cells for solid tumor immunotherapy	30
Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells	30
Three-dimensional chromatin landscapes in MLLr AML	30
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	30
Correction: Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	29
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	28
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma	28
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination	28
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs	27
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	27
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response	27
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells	26
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	26
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	26
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	26
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances	26
Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model	25
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review	25
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights	25
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy	25
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors	24
The clinical impact of IKZF1 mutation in acute myeloid leukemia	24
Antibody-drug conjugates in breast cancer: current evidence and future directions	24
New exploration of KRASG12D inhibitors and the mechanisms of resistance	23
Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012–2021: a systematic analysis	23
Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance	23
Recent advances and future perspectives in the therapeutics of prostate cancer	22
Whole exome sequencing reveals a novel LRBA mutation and clonal hematopoiesis in a common variable immunodeficiency patient presented with hemophagocytic lymphohistiocytosis	22
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	22
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model	22
Versatile function of NF-ĸB in inflammation and cancer	21
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity	21
A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression	21
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce	21
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	21
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	21
Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan	20
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy	20

Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia	20
Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications	20
Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer	20
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	19
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma	19
Downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling	19
Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms	19
Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	18
A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia	17
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications	17
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study	17
The roles of tissue resident macrophages in health and cancer	17
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	17
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	17
Immunotherapy in chronic lymphocytic leukemia: advances and challenges	16
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development	16
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	16
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	15
Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4/PDHA1 signaling and NMDAR-mediated iron export	15
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies	15
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	15
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis	14
COVID-19 vaccination associated severe immune thrombocytopenia	14
Roles of the intestinal microbiota and microbial metabolites in acute GVHD	14
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	14
Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients	14
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	14
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	14
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	14
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	14
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults	14
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	13
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	13
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	13
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer	13
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	13
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	13
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	13
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting	13
Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy	13
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma	13
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	13
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer	13
Revealing the role of the gut microbiota in enhancing targeted therapy efficacy for lung adenocarcinoma	13